Novartis: FDA Approves New Prostate Cancer Treatment
Pluvicto (lutetium Lu-177) approved for PSMA-positive metastatic prostate cancer. Novartis delays chemotherapy.
Read full article »
Novartis is a Switzerland-based multinational medicines company that researches and develops generic and pharmaceutical products for the healthcare industry.
Read more